title: [The influence of antipsychotic therapy on the cognitive functions of schizophrenic patients].
abstract: OBJECTIVE
  The aim of the present study was twofold: 1. to compare the efficacy of three antipsychotics (ziprasidone, olanzapine and perazine) in schizophrenia 2. to compare the improvement in cognitive functioning between groups treated with the three different neuroleptics.
  
  
  METHODS
  A total of 58 Caucasian patients diagnosed with paranoid schizophrenia were recruited into the study group. We used the Polish version of the CIDI (Composite International Diagnostic Interview) to obtain ICD-10 diagnoses. The intensity of psychopathological symptoms was examined using the PANSS. The patients were randomly assigned to treatment with perazine, olanzapine or ziprasidone administered as monotherapy for 3 months. The treatment efficacy was measured as a change in the PANSS (Positive and Negative Syndrome Scale) total score from baseline (T0) to 3 months (T1). The WCST (The Wisconsin Card Sorting Test) was used to measure working memory and executive functions in the evaluated patients. Wilcoxon's and Kruskal-Wallis tests were applied to compare changes in the PANSS scores between the treatment groups. To analyze the cognitive functions, Kruskal-Wallis test for the WCST parameters was used.
  
  
  RESULTS
  The three antipsychotics similarly reduced the total PANSS score. The WCST parameters in the 3 groups of examined patients using the Kruskal-Wallis test revealed some differences between the three administered antipsychotics.
  
  
  CONCLUSIONS
  Results suggest that the short-term efficacy of the atypical (olanzapine, ziprasidone) and typical (perazine) antipsychotic drugs did not differ. Based on the analysis, a conclusion can be drawn that the three neuroleptics provided similar improvements in cognitive functioning.
authors.forename: Piotr
authors.initials: P
authors.lastname: Tybura
authors.forename: Monika
authors.initials: M
authors.lastname: Mak
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Samochowiec
authors.forename: Justyna
authors.initials: J
authors.lastname: Pełka-Wysiecka
authors.forename: Anna
authors.initials: A
authors.lastname: Grzywacz
authors.forename: Elzbieta
authors.initials: E
authors.lastname: Grochans
authors.forename: Liliana
authors.initials: L
authors.lastname: Zaremba-Pechmann
authors.forename: Jerzy
authors.initials: J
authors.lastname: Samochowiec
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000627:therapeutic use*; D003071:Cognition / Q000187:drug effects*; D003072:Cognition Disorders / Q000209:etiology / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077152:Olanzapine; D010464:Perazine / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use*; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D012720:Severity of Illness Index; D016037:Single-Blind Method; D013844:Thiazoles / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D010879:Piperazines; D013844:Thiazoles; D001569:Benzodiazepines; C092292:ziprasidone; D010464:Perazine; D000077152:Olanzapine